CAM
TBIO

ClariVest Asset Management’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

ClariVest Asset Management’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-21,800
Closed -$218K – 875
2020
Q1 		$218K Buy
+21,800
New +$179K 0.01% 480

Other funds holding TBIO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClariVest Asset Management's TBIO Position: Q2 2020 in Review

ClariVest Asset Management sold out of Translate Bio, Inc. Common Stock (TBIO) in Q2 2020, closing a stake of 21,800 shares — an estimated $218K sold.

ClariVest Asset Management first reported a position in TBIO in Q1 2020 and held it in 1 quarter. The position peaked at $218K in Q1 2020. 133 funds tracked by Wall St. Rank hold TBIO as of Q2 2020.

  • ClariVest Asset Management reported no remaining Translate Bio, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • ClariVest Asset Management sold 21,800 Translate Bio, Inc. Common Stock shares in Q2 2020, an estimated $218K.
  • ClariVest Asset Management first reported a position in Translate Bio, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • ClariVest Asset Management's Translate Bio, Inc. Common Stock position peaked at $218K in Q1 2020.
  • 133 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q2 2020.

Based on ClariVest Asset Management's 13F filing for Q2 2020, filed 12 Aug 2020.